Cargando…

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19

Detalles Bibliográficos
Autores principales:	Lim, Wey Wen, Mak, Loretta, Leung, Gabriel M, Cowling, Benjamin J, Peiris, Malik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282488/ https://www.ncbi.nlm.nih.gov/pubmed/34308395 http://dx.doi.org/10.1016/S2666-5247(21)00177-4

Ejemplares similares

IMMUNE RESPONSES TO MRNA AND INACTIVATED COVID-19 VACCINES AMONG HEALTHCARE WORKERS IN HONG KONG
por: LIM, W.W., et al.
Publicado: (2023)

Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases
por: Yu, Michael Kwan Leung, et al.
Publicado: (2023)

The Effect of Age and Recent Influenza Vaccination History on the Immunogenicity and Efficacy of 2009–10 Seasonal Trivalent Inactivated Influenza Vaccination in Children
por: Ng, Sophia, et al.
Publicado: (2013)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Comparative effectiveness of 3 or 4 doses of mRNA and inactivated whole-virus vaccines against COVID-19 infection, hospitalization and severe outcomes among elderly in Singapore
por: Tan, Celine Y., et al.
Publicado: (2022)

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine
por: Zeng, Guangting
Publicado: (2022)

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1
por: Zuo, Fanglei, et al.
Publicado: (2023)

Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Increased Risk of Noninfluenza Respiratory Virus Infections Associated With Receipt of Inactivated Influenza Vaccine
por: Cowling, Benjamin J., et al.
Publicado: (2012)

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
por: Regev-Yochay, Gili, et al.
Publicado: (2022)

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients
por: Solera, Javier T, et al.
Publicado: (2023)

Construction and immunogenicity of an mRNA vaccine against chikungunya virus
por: Liu, Jingjing, et al.
Publicado: (2023)

Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021
por: Kwok, Shirley LL, et al.
Publicado: (2022)

Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus
por: So, Ho, et al.
Publicado: (2022)

Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection
por: Xiang, Tiandan, et al.
Publicado: (2021)

Impact of host genetic polymorphisms on response to inactivated influenza vaccine in children
por: Tsang, Tim K., et al.
Publicado: (2023)

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
por: Blumenthal, Kimberly G., et al.
Publicado: (2021)

Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

From a Sprint to a Marathon in Hong Kong
por: Leung, Gabriel M., et al.
Publicado: (2020)

Myocarditis after Covid-19 mRNA Vaccination
por: Verma, Amanda K., et al.
Publicado: (2021)

Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases
por: Kwok, Wang Chun, et al.
Publicado: (2023)

Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant
por: Tay, Matthew Zirui, et al.
Publicado: (2023)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Clinical development of mRNA therapies against solid tumors
por: Wu, Dawei, et al.
Publicado: (2023)

Landscape of the RBD-specific IgG, IgM, and IgA responses triggered by the inactivated virus vaccine against the Omicron variant
por: Xue, Jun-biao, et al.
Publicado: (2022)

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
por: Wu, Kai, et al.
Publicado: (2021)

Aseptic Meningitis and mRNA Coronavirus Disease 2019 Vaccine
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers
por: Yoon, Sarang K., et al.
Publicado: (2022)

Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
por: Uraki, Ryuta, et al.
Publicado: (2023)

Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion
por: Zauche, Lauren H., et al.
Publicado: (2021)

Reply: Aseptic Meningitis and mRNA Coronavirus Disease 2019 Vaccine
por: Heo, Sang Taek
Publicado: (2022)

mRNA vaccines and clinical research in Africa - From hope to reality
por: Saied, AbdulRahman A.
Publicado: (2022)

Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2
por: Ukey, Rahul, et al.
Publicado: (2022)

Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies
por: Sciascia, Savino, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Central retinal artery occlusion after Moderna mRNA-1273 vaccination
por: Chow, Sin Yu, et al.
Publicado: (2022)

Severe bullous drug reaction after COVID‐19 mRNA vaccination
por: Irmer, Marie Luise, et al.
Publicado: (2022)

Reply to Mungmunpuntipantip and Wiwanitkit: CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

Immunogenicity and protective activity of mRNA vaccine candidates against yellow fever virus in animal models
por: Medina-Magües, Lex G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_74hv696jo4tkq9fnma7k38m16u